PubMed Health⌕ Search

Biomedical subjects

E Englaro

Publications and source records attributed to E Englaro.

9 recordsLinked to original sources
PubMed1995

A brain metastasis, with no uptake of 99mTc-ECD, secondary to Hurtle cell carcinoma of the thyroid.

Visualization of cerebral perfusion with Single Photon Emission Computed Tomography (SPET) needs lipophil radiotracers which are able to cross the intact blood-brain-barrier (BBB); moreover local uptake must reflect regional cerebral blood flow. In the last decade many radiopharmaceuticals have been suggested and employed for this purpose. Recently a new molecule has been synthesized: technetium-99m-labeled ethyl cysteinate dimer (99mTc-ECD). Commonly, SPET of the brain with perfusion tracers is performed to identify ischemic regions. We describe a patient with a bulky cerebral metastasis, secondary to Hurthle cell carcinoma of the thyroid, which concentrated radioiodine. Brain metastases secondary to differentiated carcinoma of the thyroid are very rare and when treated with 131-I may provoke serious neurological problems. Therefore we decided to perform a brain SPET with 99mTc-ECD to exclude regional perfusion defects and deafferentation phenomena. Brain CT showed only the large metastasis. SPET images, reconstructed according to standard tomographic planes of the head: transverse, coronal and sagittal revealed no uptake of 99mTc-ECD within the metastasis and no regional perfusion defects related to compression phenomena or deafferentation. 99mTc-ECD has never been used to image cerebral neoplasm of whatever origin.

Adenocarcinoma↗
PubMed1983

[Bone scintigraphy in mastectomized patients with and without chemotherapy].

Follow'ups were conducted on 130 mastectomized patients, periodically subjected to bone scintigraphy in addition to conventional tests. 89 of the patients had received chemotherapy and 41 had not. The results obtained show the value of scintigraphy for both accurate staging and follow-up in such patients.

Adult↗
PubMedDate not supplied

Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study.

PURPOSE: To assess the potential value of magnetic resonance imaging (MRI) combined with 67Ga single-photon emission computed tomography (SPECT) versus computed tomography (CT) in the staging and in the monitoring of mediastinal malignant lymphoma. MATERIALS AND METHODS: Twenty-three patients, referred to our institute for the evaluation of lymphoma, underwent CT, 67Ga scan, and MRI between April 1993 and February 1996 at sequential intervals. The tests studied (MRI, 67Ga, and CT) were performed according to the following schedule: 1) before start of therapy; 2) after four courses of chemotherapy; and 3) 2, 6, 12, and 18 months after the end of treatment. RESULTS: All patients studied at the time of diagnosis had abnormal gallium accumulation in the mediastinum as well as pathologic CT and pathologic signal intensity at MRI. Six months after the end of treatment full consistency was found between the results of MRI and SPECT, whereas during treatment and 2 months after the end of therapy MRI and 67Ga scan were not in agreement in nine patients. In the 23 patients in follow-up, in CT there were nine false-positive and three false-negative findings; in SPECT three false negatives; in MRI one false positive and one false negative. CONCLUSION: MRI can give morphologic information similar to CT, even superior due to multiplanarity and with major precision in the distinction between fibrosis and active disease. MRI is thus an alternative to CT. The association with SPECT allows a great diagnostic accuracy in the positive and negative predictive value.

Adolescent↗